All In Biotech

Drug Trial Radar · NCT05602792

A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors

A Phase I/IIa Study to Assess the Safety, Tolerability, Biodistribution and Pharmacodynamic of T3011 Herpes Virus Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Nov 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

233

Planned (sponsor's estimate)

Start

Apr 21, 2020

Primary completion

Jul 2023

Study completion Jan 2024

Sponsor

Lead sponsor
ImmVira Pharma Co. LtdIndustry
Sponsor type
Industry
First posted
Nov 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I/IIa Study of the Safety and Tolerability of T3011 Administered via Intratumoral Injection in Patients with Advanced Solid Tumors

Conditions

  • Advanced Solid Tumor
  • Sarcoma
  • HNSCC
  • Breast Cancer
  • Esophagus Cancer
  • NSCLC
  • Non-melanoma Skin Cancer

Interventions

  • T3011Biological

    T3011 will be administered through intratumoral injection in patients with advanced solid tumors.

  • T3011Biological

    T3011 will be administered through intratumoral injection in patients with sarcoma.

  • T3011Biological

    T3011 will be administered through intratumoral injection in patients with Malignant head and neck tumor.

  • T3011Biological

    T3011 will be administered through intratumoral injection in patients with breast cancer.

  • T3011Biological

    T3011 will be administered through intratumoral injection in patients with esophagus cancer.

  • T3011Biological

    T3011 will be administered through intratumoral injection in patients with lung cancer.

  • T3011Biological

    T3011 will be administered through intratumoral injection in patients with non-melanoma skin cancer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. In part I and part II, Evaluate the safety and tolerability of escalating doses of single dose and multiple dose IT T3011.Characterize DLTs and identify the MTD of IT T3011.Time frame: Up to 2 years from first dose of T3011
  2. In part III, Evaluate the safety of multiple dose IT T3011 in the following indications,including sarcoma, Malignant head and neck tumor, breast cancer, esophagus cancer, lung cancer and non-melanoma skin cancer.Time frame: Up to 2 years from first dose of T3011

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China · Recruiting

  • Beijing Jishuitan Hospital

    Beijing, China · Recruiting

  • Ninth People's Hospital,Shanghai Jiao Tong University School to Medicine

    Shanghai, China · Recruiting

  • Fudan University Cancer Hospital

    Shanghai, China · Recruiting

  • Zhongshan Hospital

    Shanghai, China · Recruiting

  • Shanghai Sixth People's Hospital

    Shanghai, China · Not yet recruiting

  • The Second People's Hospital of Shenzhen

    Shenzhen, China · Recruiting

  • Anhui Provincial Hospital

    Hefei, Anhui, China · Recruiting

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • The Fifth Affiliated Hospital of Sun Yat-sen University

    Guanzhou, Guangdong, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Wuhan Union Hospital

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China · Recruiting

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • The First Affiliated Hospital of Zhejiang University Medical College

    Hanzhou, Zhejiang, China · Recruiting

  • Zhejiang Provincial People's Hospital

    Hanzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.